The clinician managing schizophrenia prescribes antipsychotic regimens, manages treatment-resistant schizophrenia (TRS), coordinates metabolic risk reduction, and makes complex treatment decisions including clozapine initiation. TRS is defined as failure to achieve adequate symptom response after 2 adequate antipsychotic trials (adequate dose for adequate duration of 6-8 weeks each). TRS affects approximately 30% of schizophrenia patients. Clozapine is the ONLY medication with proven superiority for TRS, yet it is significantly underutilized (only 5-10% of eligible patients receive it, despite 30-60% response rate). Barriers include: REMS monitoring requirements, side effect profile, prescriber reluctance, and patient/family hesitancy. The clinician should advocate for earlier clozapine use based on evidence that delays in clozapine initiation worsen outcomes. Clozapine pharmacology is unique: relatively weak D2 blockade (explaining low EPS and TD risk), high 5-HT2A affinity, significant muscarinic, histaminic, and alpha-adrenergic blockade. Clozapine monitoring includes: ANC (agranulocytosis risk 1-2%, highest in first 6 months), metabolic panel (highest weight gain and diabetes risk), cardiac monitoring (myocarditis risk in first month -- monitor troponin, CRP, echo), and bowel function (constipation leading to ileus). The clinician also manages first-episode psychosis (FEP),...